» Articles » PMID: 35327979

Role of MiRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2022 Mar 25
PMID 35327979
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative diseases originate from neuronal loss in the central nervous system (CNS). These debilitating diseases progress with age and have become common due to an increase in longevity. The National Institute of Environmental Health Science's 2021 annual report suggests around 6.2 million Americans are living with Alzheimer's disease, and there is a possibility that there will be 1.2 million Parkinson's disease patients in the USA by 2030. There is no clear-cut universal mechanism for identifying neurodegenerative diseases, and therefore, they pose a challenge for neurobiology scientists. Genetic and environmental factors modulate these diseases leading to familial or sporadic forms. Prior studies have shown that miRNA levels are altered during the course of the disease, thereby suggesting that these noncoding RNAs may be the contributing factor in neurodegeneration. In this review, we highlight the role of miRNAs in the pathogenesis of neurodegenerative diseases. Through this review, we aim to achieve four main objectives: First, we highlight how dysregulation of miRNA biogenesis led to these diseases. Second, we highlight the computational or bioinformatics tools required to identify the putative molecular targets of miRNAs, leading to biological molecular pathways or mechanisms involved in these diseases. Third, we focus on the dysregulation of miRNAs and their target genes leading to several neurodegenerative diseases. In the final section, we highlight the use of miRNAs as potential diagnostic biomarkers in the early asymptomatic preclinical diagnosis of these age-dependent debilitating diseases. Additionally, we discuss the challenges and advances in the development of miRNA therapeutics for brain targeting. We list some of the innovative strategies employed to deliver miRNA into target cells and the relevance of these viral and non-viral carrier systems in RNA therapy for neurodegenerative diseases. In summary, this review highlights the relevance of studying brain-enriched miRNAs, the mechanisms underlying their regulation of target gene expression, their dysregulation leading to progressive neurodegeneration, and their potential for biomarker marker and therapeutic intervention. This review thereby highlights ways for the effective diagnosis and prevention of these neurodegenerative disorders in the near future.

Citing Articles

Bee Pollen Phytochemicals and Nutrients as Unequaled Pool of Epigenetic Regulators: Implications for Age-Related Diseases.

Kacemi R, Campos M Foods. 2025; 14(3).

PMID: 39941940 PMC: 11816923. DOI: 10.3390/foods14030347.


Exosomal MicroRNAs in Alzheimer's Disease: Unveiling Their Role and Pioneering Tools for Diagnosis and Treatment.

Alhenaky A, Alhazmi S, Alamri S, Alkhatabi H, Alharthi A, Alsaleem M J Clin Med. 2024; 13(22).

PMID: 39598105 PMC: 11594708. DOI: 10.3390/jcm13226960.


Upregulated miR-10b-5p as a potential miRNA signature in amyotrophic lateral sclerosis patients.

Dash B, Freischmidt A, Helferich A, Ludolph A, Andersen P, Weishaupt J Front Cell Neurosci. 2024; 18:1457704.

PMID: 39588282 PMC: 11586771. DOI: 10.3389/fncel.2024.1457704.


MicroRNAs regulation in Parkinson's disease, and their potential role as diagnostic and therapeutic targets.

Shaheen N, Shaheen A, Osama M, Nashwan A, Bharmauria V, Flouty O NPJ Parkinsons Dis. 2024; 10(1):186.

PMID: 39369002 PMC: 11455891. DOI: 10.1038/s41531-024-00791-2.


Kernel Bayesian logistic tensor decomposition with automatic rank determination for predicting multiple types of miRNA-disease associations.

Ma Y, Ma Y PLoS Comput Biol. 2024; 20(7):e1012287.

PMID: 38976761 PMC: 11257412. DOI: 10.1371/journal.pcbi.1012287.


References
1.
Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

2.
Bilen J, Liu N, Burnett B, Pittman R, Bonini N . MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell. 2006; 24(1):157-63. DOI: 10.1016/j.molcel.2006.07.030. View

3.
Reddy P, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva C . A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease. Biochem Biophys Res Commun. 2016; 483(4):1156-1165. PMC: 5343756. DOI: 10.1016/j.bbrc.2016.08.067. View

4.
Lukiw W, Alexandrov P, Zhao Y, Hill J, Bhattacharjee S . Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Neuroreport. 2012; 23(10):621-6. PMC: 4467540. DOI: 10.1097/WNR.0b013e32835542b0. View

5.
Fiore R, Khudayberdiev S, Christensen M, Siegel G, Flavell S, Kim T . Mef2-mediated transcription of the miR379-410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. EMBO J. 2009; 28(6):697-710. PMC: 2647767. DOI: 10.1038/emboj.2009.10. View